Has the fever broken for the high momentum stocks? Nvidia running out of steam this week, as some other high fliers also pull back. Is this just a bump in the road or the beginning of a summer slowdown? Plus Sarepta’s big surge. The biotech company getting expanded approval from the FDA for its muscular dystrophy drug. What the CEO says is next for the company.   Fast Money Disclaimer  

There’s a new biggest bull on Wall Street, as Evercore’s Julian Emanuel ups his year-end price target on the S&P by 25% to a whopping 6,000/ What’s going to drive those returns and how should you play the market? Plus Industrials have been struggling so far in 2024, but one top technician says these names are about to witness a turnaround. We go off the charts to get the details.   Fast Money Disclaimer